Aerocom Healthcare

aerocomhealthcare.com

Based in Denver, Colorado, Aerocom Healthcare is the exclusive provider of Aerocom pneumatic tube systems for the healthcare market in North America. We deliver a complete turnkey solution, offering system design consulting, BIM coordination, installation and project management support for hospitals, architects and general contractors. After completion, we provide complete training and ongoing customer support programs for healthcare clients. Aerocom Healthcare is staffed by professionals with years of pneumatic tube system experience. As a result, our consultation, system design and project execution meets high customer expectations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

news image

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

news image

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More
news image

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More
news image

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More